



43rd National Congress of the Italian Society of Pharmacology

Creating value through pharmacological research

November 25–28, 2026

Centro Congressi Lingotto

Via Nizza 280, Turin

CROSS-CUTTING TOPICS

- Regulatory aspects
- Drug policies
- Market access
- Therapeutic appropriateness
- New care paradigms
- Medical devices
- Companion diagnostics
- Clinical research
- Digital health
- Personalised medicine
- New technologies and approaches
- In silico simulations
- Drug assessments
- Drug safety
- Pharmacogenetics
- Gender pharmacology
- Paediatric pharmacology
- Pharmacovigilance, pharmacoepidemiology, pharmacoeconomics & Real World Evidence (RWE)
- Addiction disorders
- Innovation, ethics and sustainability
- Health poverty
- Basic pharmacology
- Toxicology
-

SPECIFIC TOPICS

- Chemotherapy and vaccines
- Pharmacognosy, phytotherapy and nutraceuticals
- Digestive system pharmacology

Segreteria Scientifica



Provider e Segreteria Organizzativa





- Pain pharmacology
- Cancer pharmacology
- Regenerative pharmacology
- Ocular pharmacology
- Cardiovascular and metabolic pharmacology
- Endocrine system pharmacology
- Inflammation and immune system pharmacology
- Nervous system pharmacology
- Respiratory system pharmacology
- Infectious diseases
- Rare diseases
- Advanced therapies

Scientific Chair:

Armando Genazzani - Università degli Studi di Torino. SIF President

Scientific Committee:

Michele Biagioli - Università degli Studi di Perugia

Mariarosaria Bucci - Università degli Studi di Napoli "Federico II", Napoli

Annamaria De Luca - Università degli Studi "Aldo Moro", Bari

Fabrizio Gardoni - Università degli Studi di Milano

Armando Genazzani - Università degli Studi di Torino, SIF President

Carla Ghelardini - Università degli Studi di Firenze

Maria Antonietta Riemma - Università degli Studi Campania "Luigi Vanvitelli", Napoli

Maria Angela Sortino - Università degli Studi di Catania

Segreteria Scientifica



Provider e Segreteria Organizzativa





Scientific Rationale

A congress of a learned society serves to showcase the activities and research of the members, to imagine and shape together the future of the discipline, and to bring together professionals with similar backgrounds to allow them to establish collaborations and exchange best practices. The Congress in Turin embraces all three of these missions.

Ample space will be given, as usual, to high-quality research. Yet, there are important changes compared to the past. The traditional oral communications have been converted into topic symposia organized exclusively by the early-career pharmacology members. Furthermore, an effort has been made, whenever possible, to bring together basic and clinical content. Indeed, while **a good researcher in any discipline is measured by the ability to answer relevant scientific questions** and thus push the boundaries of knowledge, **a pharmacologist has a further challenge**: to move transversally across all areas of drug development, from target identification to market access dynamics, encompassing preclinical, non-clinical and clinical research, evidence generation and evaluation, as well as regulation and market dynamics.

The congress aims to be a showcase of the golden age we are experiencing. Drugs are being developed much more rapidly than in the past, a significantly greater number of drugs is being developed, and the available technologies have increased substantially. This new wealth is accompanied by increased complexity at every level and therefore by the need for significant changes. Proximity of care, system sustainability, telemedicine, translational medicine, precision medicine, prevention, and artificial intelligence are no longer slogans but are embedded in the pharmaceutical world we live in. In this context, the role of the pharmacologist is central, as the transversal nature of the profession will bring significant value to the system.

Finally, the congress will address many of the key cross-cutting themes at the heart of current discussions, from high-quality basic research to new tools in clinical research, from real-world evidence to regulatory uncertainties, from evidence-based medicine to the personalization of therapies, including gender pharmacology, and from economic sustainability to organizational innovation.

The congress will bring together leading experts from academia, the public and private sectors, thereby fostering a high-level and productive scientific environment. To support this process, structured networking opportunities will be provided for trainees, members serving on Ethics Committees, professionals working in Phase I Units and molecular tumor boards, and members of the SIF sections.

Segreteria Scientifica



SOCIETÀ ITALIANA DI FARMACOLOGIA

Provider e Segreteria Organizzativa





Continuing Medical Education (CME) Area Scientific Program

MEETING ROOM ROMA

25 November 2026

13.30 – 15.30 SY24 Pharmacological innovations for the management of metabolic disorders and their comorbidities

Chairpersons: Marzia Friuli, Laura Rizzi

13.30 Targeting the liver-brain axis in diabetes-associated Alzheimer's disease: hepatic NLRP3 as a pharmacological node **Claudio Pirozzi**

13.45 Impact of ANGPTL3-targeted therapies on lipids and apolipoproteins: a meta-analysis of randomized controlled trials **Elena Olmastroni**

14.00 Beyond the trip: the metabolic action of psilocybin in steatotic liver disease **Anna Signor**

14.15 Competing risk of death and neurological outcomes in elderly diabetic patients treated with GLP-1 receptor agonists **Vera Battini**

14.30 Effects of N-acyl ethanolamines on obesity-induced cardiometabolic alterations **Federica Comella**

14.45 Pharmacological modulation of the paracannabinoid system in diet-induced overweight: insights into early cardiac dysfunction **Alessia Campagna**

15.00 Cholinergic stimulation promotes resilience and PD-L1 expression in human terminally differentiated β -cells: implications for novel Type 1 Diabetes strategies **Francesco Petragnano**

15.15 Adolescent high-fat diet programs a lipotoxic and bioenergetically inefficient skeletal muscle phenotype: protective role of oleoylethanolamide **Christian Sepe**

26 November 2026

8.30 – 10.00 SY01 From visceral to somatic pain: mechanisms, pathways, and therapeutic targets

Chairpersons: Andrea Maria Morace, Stefania Ceruti

8.30 μ -opioid receptor in NK cells as a potential biomarker for neuropathic pain: evidence from the CCI model and modulation by bergamot polyphenolic fraction **Lucia Carmela Passacatini**

8.45 Decoding vulvodynia: from pelvic sensitivity to central pain processing **Michela Perrone**

9.00 Exploring the dual role of *Mangifera indica* L. in alleviating abdominal visceral pain and inflammation **Anna Schettino**

9.15 Dissecting the gut-vulva axis: translational insights from IBS-associated vulvodynia and evaluation of glucosinolates-based therapy **Elena Lucarini**

9.30 From intestinal epithelium to visceral pain: molecular mechanisms involved in IBS **Sofia Faggin**

9.45 Dissecting MOR-CB1 interactions in neuronal cell models: implications for opioid-cannabinoid co-treatment in chronic pain **Gaia Lusoli**

Segreteria Scientifica

Provider e Segreteria Organizzativa



10.00 – 11.00 S24 Modelling and simulation as drivers of innovation in pharmacology

Chairpersons: Gianluca Miglio, Federico Pea

10.00 From data to model **Oscar Della Pasqua**

10.15 From mechanistic knowledge to translational impact: a systems biology and QSP perspective
Enrico Domenici

10.30 Regulatory impact of PK and PD modelling and simulation: expectations and practical cases
Serena Zamponi

10.45 Hypoparathyroidism: from a conventional approach to the hormonal therapy **Maria Luisa Brandi**

11.00 – 12.30 S5 Vulnerability to relapse: behavioral, circuit and molecular fingerprints

Chairpersons: Roberto Ciccocioppo, Fabio Fumagalli

11.00 Cocaine withdrawal during adolescence alters hippocampal neuro-glia interaction dynamics and excitatory–inhibitory synapses in response to an acute stress **Lucia Caffino**

11.20 Impact of adolescent social exclusion on relapse susceptibility to alcohol seeking and stress-related behaviors in male and female rats **Esi Domi**

11.40 Dorsal raphe projections to the central amygdala and nucleus accumbens drive methamphetamine relapse **Daniele Caprioli**

12.00 Multidimensional addiction profiling in outbred rats: from individual differences to medication development **Giordano de Guglielmo**

14.30 – 16.00 S18 Optimizing polypharmacy management in complex patients: key priorities, tools, and strategic approaches

Chairpersons: Romano Danesi, Amelia Filippelli

14.30 Medication reviews and pharmacogenetics: the critical role of data integration **Valeria Conti**

14.45 Medication review in different care settings, constraints and potential benefits **Elisabetta Poluzzi**

15.00 Artificial Intelligence in medication review and deprescribing services **Gianluca Trifirò**

15.15 Clinical assessment of drug–drug interactions: insights from a national pilot study **Riccardo Giossi**

15.30 AIFA's Position Paper on the implementation of precision medicine **Robert Nisticò**

16.00 – 17.30 S1 Chronic pain 2.0: emerging mechanisms and therapeutic strategies

Chairpersons: Laura Micheli, Paola Sacerdote

16.00 Emerging strategies for pain management in Fabry Disease, a rare genetic disorder **Silvia Franchi**

16.15 Proteome-wide characterization of neuroinflammatory signatures in morphine-exposed spinal tissue: modulation by ultramicrosized palmitoylethanolamide **Alessandra Toti**

16.30 Effect of conditioned diet in a model of early life-induced widespread pain: potential role of HCAR2 receptors **Carmela Belardo**

16.45 Neuroinflammatory mechanisms in opioid-related side effects: insights from methadone rotation **Laura Rullo**

17.00 NanoBEO: transdermal nanotechnology for the management of pain and agitation in severe dementia **Damiana Scuteri**

Segreteria Scientifica

Provider e Segreteria Organizzativa



27 November 2026

8.30 – 9.30 SY25 Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions

Chairpersons: Vincenzo Brancaleone, Simona Pace

8.30 Dysfunctional gut microbiota–endocannabinoid axis exacerbates skeletal muscle and brain deficits in Duchenne muscular dystrophy (DMD) **Noemi Di Muraglia**

8.45 Sex-dependent modulation of audiogenic seizures by ketogenic diet in a GluN2A(N615S) model of GRIN-related encephalopathy **Alessandra Lodi**

9.00 Sex-specific lipid mediator profile drives pulmonary fibrosis pathogenesis in mice **Danilo D'Avino**

9.15 Sex-specific pharmacotherapy and vascular stiffness in hypertension **Marialuisa Sveva Marozzi**

09.30 – 11.00 S14 Psychedelics and more: innovative treatments for neurodevelopmental diseases and therapeutic challenges

Chairperson: Riccardo Brambilla

9.30 Sex dependent behavioral and brain molecular effects of psilocybin in mice exposed to early life stress **Laura Musazzi**

9.50 Psilocybin in neurodevelopmental disorders: preclinical insights into mechanisms of action **Viviana Trezza**

10.10 Cortico-striatal pathophysiology for neurodevelopmental disorders associated with 16p11.2 CNVs: implications for therapeutic targeting **Ilaria Maria Morella**

10.30 SHANK3 related autism: from cell biology to new treatment opportunities **Chiara Verpelli**

11.00 – 12.30 S33 From maternal well-being to offspring mental health: molecular determinants of intergenerational vulnerability

Chairpersons: Miriam Melis, Marco Andrea Riva

11.00 Mechanistic insights into how gestational stress programs long-term vulnerability **Alessia Marchesin**

11.15 Examine the association between maternal cannabis use and sex-specific dysfunctional mitochondrial bioenergetics leading to dopamine-related psychopathological traits in the offspring **Federico Brandalise**

11.30 Maternal depression and psychosocial stress, before and during pregnancy, alter neurodevelopmental trajectories of the progeny by remodeling placental transcriptional and epigenetic landscapes **Juliet Richetto**

11.45 Demonstrate how post-parturition alcohol exposure disrupts neuroadaptations driven by motherhood **Sebastiano Bariselli**

12.00 Deciphering the role of IL-17A in ASD-like phenotypes: evidence from a maternal immune activation mouse model **Anna Maria Tartaglione**

12.15 Sex-divergent effects of cannabidiol treatment in rats prenatally exposed to VPA **Erica Zamberletti**

Segreteria Scientifica

Provider e Segreteria Organizzativa



14.30 – 16.00 S27 Therapeutic advances in developmental and epileptic encephalopathies: present and future

Chairpersons: Emilio Russo, Maurizio Tagliatela

14.30 From genotype-phenotype correlations to emerging therapeutic strategies in SCN1A-related neurological disorders **Paola Imbrici**

14.50 Gut Microbiota in Angelman Syndrome: toward biomarkers and novel therapeutic strategies **Carmen De Caro**

15.10 Investigating sex differences in a validated model of GRIN2A-related DEE: psychopathological and therapeutic implications **Ilaria Bertocchi**

15.20 Targeted therapies in KCNQ2-related developmental and epileptic encephalopathies **Francesco Miceli**

28 November 2026

8.30 – 10.00 SY27 Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms

Chairpersons: Felipe Borges Almeida, Adriano Lama

8.30 RACK1 modulation as a mechanistic platform for screening immunotoxic effects of endocrine disrupting chemicals **Mirco Masi**

8.45 Environmental chemicals as drivers of neuronal vulnerability: glutamatergic receptor dynamics in critical developmental windows **Melania Maria Serafini**

9.00 Nanoplastic co-exposure as an emerging environmental driver of metabolic dysfunction in liver and adipose tissue **Stefania Melini**

9.15 Downregulation of Kv7 channels contributes to angiotensin-II induced modulation of neuronal activity in brain areas controlling sympathetic tone **Stefania Iervolino**

9.30 Invisible invaders: subacute nanoplastic ingestion drives neuroinflammation via the gut-brain axis **Federico Ciceri**

9.45 Early life stress alters hypothalamic-peripheral metabolic signaling linking psychiatric and metabolic vulnerability **Ilari D'Aprile**

10.00 – 11.30 S16 Biological therapies and molecular target drugs in chronic inflammatory autoimmune diseases: from basic and translational research to clinical evidence

Chairpersons: Massimo Collino, Ciriana Orabona

10.00 A new frontier in IL-17 antagonism: FM15TM, a first-in-class linear small peptide with translational potential in chronic inflammation and autoimmune diseases **Francesco Maione**

10.20 Rewriting IMIDs: the disease-modifying potential of anti-IL-23 therapies **Luca Antonioli**

10.40 Novel imaging-based methods for validating immunopharmacology in vivo **Ishii Masaru**

11.00 Biologic and targeted therapies in autoimmune diseases: current perspectives and clinical challenges **Annamaria Iagnocco**

Segreteria Scientifica

Provider e Segreteria Organizzativa



NON CME Area PRELIMINARY SCIENTIFIC PROGRAMME

25 November 2026

AUDITORIUM

- | | |
|-------------|---|
| 15.30-16.00 | Opening Ceremony |
| 16.00-17.00 | Plenary Lecture
From unmet clinical needs to better care: lessons from a career in oncology research
Introduced by Armando Genazzani
Speaker: Lucia Del Mastro |
| 17.00-18.00 | Plenary Round Table
Challenges and opportunities for pharmaceutical research in Italy: education, quality and transferability
Chairpersons: Giuseppe Cirino, Monica Diluca
Participants: Robert Nisticò, Giulio Pompilio, TBD |
| 18.00-19.00 | Plenary Round Table
Access to therapies and early access pathways in Italy
Chairman: Armando Genazzani
Participants: Massimo Di Maio, Claudio Jommi, Robert Nisticò, Annalisa Scopinaro |

MEETING ROOM MADRID

- 13.30 – 15.30 SY08 Synaptic and cellular communication in neurodegeneration: mechanisms and therapeutic opportunities**
Chairpersons: Roberta Facchinetti, Giulia Sita
- 13.30 Co-ultramicrosized palmitoylethanolamide/luteolin inhibits astrocyte-mediated oligodendrocyte dysfunction in an in vitro model of β -amyloid toxicity **Claudia Ciarla**
- 13.45 Targeting lysosomal dysfunction via a GTD-released GCase modulators in GBA1 and Grn mouse models **Chiara Bertasini**
- 14.00 Ca^{2+} -storing organelles as druggable targets in astrocyte-neuron communication during Alzheimer's disease progression **Silvia Piccirillo**
- 14.15 Purple corn anthocyanins protect against the progression of multiple sclerosis and associated trigeminal pain reducing glial activation **Benedetta Riboldi**
- 14.30 Investigating glymphatic dysfunction in persistent pain: AQP4 downregulation and CSF flow alteration in a mouse model of oxaliplatin-induced neuropathy **Clara Ciampi**
- 14.45 Astroglial endoplasmic reticulum-mitochondria interaction as a possible target for Alzheimer's disease treatment **Giulia Dematteis**
- 15.00 Deciphering the role of CAP2 in neuronal mitochondrial vulnerability in Alzheimer's disease **Ramona Stringhi**
- 15.15 Cellular Prion Protein (PrPc) and TGF β 1-receptors antagonistically settle microglial activity in response to tau oligomers **Giorgia Serena Gullotta**

Segreteria Scientifica

Provider e Segreteria Organizzativa



MEETING ROOM DUBLINO

13.30 – 15.30 SY15 Phytotherapeutics and the central nervous system

Chairpersons: Vittoria Borgonetti, Antonella Di Sotto

13.30 Neurological adverse reactions associated with cannabis-derived products **Ilaria Ammendolia**

13.45 Retinal protective effects of cannabidiol in an in vivo model of AMPA-induced excitotoxicity
Federica Conti

14.00 From pain to relief: plasma cannabinoid levels in patients using cannabis oil extracts **Alessandra Manca**

14.15 Association of *Commiphora myrrha* extract and cannabidiol: combined stimulation of the opioid and cannabinoid system for the treatment of neuropathic pain **Samuele Trisolini**

14.30 Neuroimmune modulation by chronic ellagic acid administration in EAE mice: bridging noradrenergic system and synaptic pruning **Veronica Torre**

14.45 Ellagic acid-loaded nanovesicles rescue LTP impairment and neuroinflammation in an AD ex-vivo model **Nunzia Maisto**

15.00 Genetic deletion of Kv7.5 channel impairs the blood-brain barrier, enhances seizure susceptibility, and abolishes the anticonvulsant effect of the rosemary-derived small molecule carnosic acid **Camilla Celentano**

15.15 Early chronic low-dose psilocybin promotes visual cortex plasticity and functional recovery after occipital stroke **Sofia Nasini**

MEETING ROOM BERLINO

13.30 – 15.30 SY10 Post-marketing surveillance and appropriate drug utilization

Chairpersons: Maria Antonietta Barbieri, Salvatore Crisafulli

13.30 Assigning Defined Daily Dose (DDD) to ophthalmological antibiotics (ATC S01AA): Why is it challenging? Why is it important? **Angela Boccia**

13.45 Real-World Effectiveness and safety of DOACs vs VKAs according to anticoagulation quality in patients with atrial fibrillation and cancer: toward appropriate anticoagulant selection **Gianluca Gazzaniga**

14.00 Therapeutic switching and prescribing appropriateness in pregnancy: a retrospective study from the PERSONA project **Giada Crescioli**

14.15 Neuropsychiatric adverse events with Anti-IL17 approved for plaque psoriasis: an analysis from the Food and Drug Administration adverse event monitoring system **Giulia Russo**

14.30 Assessing the safety of pediatric biologics using a multi-step signal detection approach: a VigiBase study **Nicoletta Luxi**

14.45 Neuropsychiatric disorders during treatment for ADHD with atomoxetine and methylphenidate: a systematic review and meta-analysis of randomised controlled trials **Raffaella Di Napoli**

15.00 Polypharmacy and potential drug misuse in patients with type 2 diabetes mellitus: a Swedish register-based drug utilization study **Antonietta Anatriello**

15.15 Implementation and impact of pharmacogenetics, therapeutic drug monitoring and medication review on optimizing therapy effectiveness and mitigating adverse drug reactions in pediatric patients
Paolo Dalla Zuanna

Segreteria Scientifica

Provider e Segreteria Organizzativa



MEETING ROOM LONDRA

13.30 – 15.30 SY11 Therapeutic drug monitoring as a measure of appropriateness in adult and pediatric populations

Chairpersons: Bianca Maria Goffredo, Marianna Lucafò

13.30 Safety and efficacy of a new optimized in-silico deferiasirox dose rationale for the treatment of iron overload in paediatric patients undergoing haematopoietic stem cell transplantation **Giammarco Baiardi**

13.45 Optimal plasma cut-off value of active ATG to prevent aGVHD and the role of miRNA320 in pediatric HSCT recipients **Debora Curci**

14.00 Saliva-based therapeutic drug monitoring of antiseizure medications: a non-invasive approach in Lennox-Gastaut Syndrome **Francesca Dattrino**

14.15 Plasma cannabidiol concentrations in real-world clinical practice: impact of dose and concomitant antiseizure medications **Alessia Cafaro**

14.30 Use of PK/PD modeling techniques for the optimization and personalization of antibiotic therapy in critically ill pediatric patients undergoing extracorporeal purification techniques **Raffaele Simeoli**

14.45 Plasma concentration profile of ropivacaine in arterial blood following erector spinae plane block in thoracic and cardiac surgical procedures **Alice Palermi**

15.00 Optimizing vancomycin dosing in non-critically ill patients: PK/PD target attainment and development of a renal function-based dosing nomogram **Francesco Russiani**

15.15 Integrated CYP3A4 and CYP3A5 genotyping enables precision tacrolimus dosing in kidney transplant recipients **Michelangelo Rottura**

MEETING ROOM ISTANBUL

13.30 – 15.30 SY26 Precision medicine: oncology and beyond

Chairpersons: Gloria Ravegnini, Rossana Roncato

13.30 Peripheral biomarkers to support a personalized approach in severe mental disorders **Anna Meloni**

13.45 Gut microbiota-driven modulation of thiopurine response: towards precision medicine in IBD **Martina Franzin**

14.00 Revealing sex-specific treatment outcomes and molecular signatures in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy: implications for personalized therapy **Noemi Milan**

14.15 Optimizing DPYD pharmacogenetics: from variant-specific dosing to haplotype-based risk stratification **Martina Gambron**

14.30 UGT1A1*28 polymorphism does not predict neuropsychiatric drug toxicity in HIV-positive patients **Emanuela De Bellis**

14.45 Optimizing precision medicine in FLT3-mutated acute myeloid leukemia: translational safety evaluation of FLT3 inhibitors through meta-analysis and real-world pharmacovigilance **Cecilia Cagnotta**

15.00 Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials **Consiglia Riccardi**

15.15 Toward personalized imatinib therapy in GIST: sex differences and the clinical value of Therapeutic Drug Monitoring in a real-world Italian cohort **Eleonora Cecchin**

Segreteria Scientifica

Provider e Segreteria Organizzativa



MEETING ROOM PARIGI

13.30 – 15.30 SY12 Tissue damage and the immune microenvironment: emerging immunoregulatory mechanisms and therapeutic perspectives

Chairpersons: Massimo Collino, Benedetta Pieroni

13.30 Targeting the H₂S–FPR2 axis: an emerging immunoregulatory mechanism in tissue damage and inflammation resolution **Ludovica Lela**

13.45 Blueprint mapping reveals a therapeutic window for topical anti-IL-17A/F monoclonal antibodies targeting the psoriatic immune microenvironment **Anella Saviano**

14.00 NR2F6: a novel immunoregulatory node linking tissue microenvironment and immune activation **Giorgia Manni**

14.15 Gut-directed NLRP3 blockade limits systemic tissue damage and restores function in a model of aging-related decline **Giulia Valdiserra**

14.30 Targeting αMβ2 integrin to reprogram immune cell function: from inflammation to tumor microenvironment remodelling **Andrea Maurizio**

14.45 Long intergenic non-coding RNA-p21 in juvenile idiopathic arthritis: a novel mediator and biomarker of methotrexate response **Federico Riccardi**

26 November 2026

12.30 – 14.00 POSTER SESSION 1

17.30-19.00 POSTER SESSION 2

MEETING ROOM MADRID

8.30 – 9.30 SY21 De novo drug design, polypharmacy, repurposing, and AI-driven discovery in rare diseases

Chairpersons: Giorgia Dinoi, Andrea Tarozzi

8.30 Drug repurposing in pediatric rare diseases: a retrospective analysis of off-label prescriptions at the University Hospital of Catania **Giorgia Loreto**

8.45 Integration of genome-wide association, bioinformatics, and machine learning studies for drug repurposing in Huntington's disease **Barbara Pagliarani**

9.00 The p.L689F mutation of Nav1.4 sodium channel in myotonia permanens: a functional and pharmacological study **Paola Laghetti**

9.15 Bridging in silico and in vitro approaches to identify Kv1.1 and Kv1.2 potassium channels modulators for associated neurological disorders **Alessandro Giovanni Cerchiara**

9.30-12.30 S22 Preclinical and clinical research in rare disorders

Chairpersons: Annamaria De Luca, Enrico Costa

9.30 Uncovering REST as a prognostic factor and therapeutic target in ALS **Luigi Formisano**

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 10.00 Bridging preclinical research and clinical evidence for use of SGLT2 inhibitors in Lafora Disease
Antonella Liantonio
- 10.30 Adaptive clinical trial design and RWE: how to overcome evidence gap in rare disease research
Gianluca Trifirò
- 11.00 TK2d: optimizing patient pathways through early recognition, differential diagnosis and multidisciplinary management **Caterina Garone**
- 11.30 Clinical research in rare primary immunodeficiencies: from study design to drug approval and beyond
Viviana Moschese
- 12.00 X-linked Adrenoleukodystrophy (X-ALD): from pathophysiology to emerging therapeutic strategies
Davide Tonduti

SPONSORED SESSION - Blueprint

- 14.30 – 15.30 How precision medicine is transforming rare diseases: the avapritinib story**
Simone Baldovino, Armando Genazzani, Massimo Triggiani

SPONSORED SESSION – Sobi - Swedish Orphan Biovitrum

- 15.30-16.00 Disease understanding in complement-mediated disorders: translating biology into targeted Immunopharmacology**

Chairperson: Valentina Drago

Speaker: Carlo Riccardi

- 16.00 – 17.30 S28 Drug repurposing for neuropharmacology: translational paths from neurodevelopmental disorders to brain tumors**

Chairpersons: Emanuela Esposito, Gabriele Stocco

- 16.00 Identification of the antipsychotic JNJ-37822681 as a novel Kv7 opener for epilepsy treatment: challenges and opportunities **Maurizio Tagliatela**

- 16.20 Crossing boundaries: a fly avatar platform for high-throughput cancer drug repurposing in ASD
Claudia Bagni

- 16.40 Drug repositioning strategy for Spinal Muscular Atrophy: from preclinical studies to therapeutic opportunities **Marina Boido**

- 17.00 Key role of preclinical studies in repurposing strategies for complex rare disorders: lessons from neuromuscular diseases **Brigida Boccanegra**

MEETING ROOM DUBLINO

- 08.30 – 10.00 SY29 - Biotechnological drugs in modern pharmacology: emerging classes and therapeutic innovations**

Maria Antonietta Barbieri, Valerio Ciccone

- 8.30 Emerging RNA therapeutics: miR-22 inhibition for the treatment of neuropathic pain **Francesco Margiotta**

- 8.45 Drugging the "undruggable": rewiring cancer through transcription factors degraders **Sara Boumya**

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 9.00 Immune landscape of chronic rhinosinusitis with nasal polyps: modulation by dupilumab therapy
Benedetta Romano
- 9.15 The potential of near-infrared photobiomodulation in assisted reproduction: effects on sperm motility and oocyte maturation **Matilde Balbi**
- 9.30 Exploring gene editing tools for astrocyte-specific therapy in Alexander disease **Irene Capuano**
- 9.45 Olipudase alfa allergy: omalizumab-aided desensitization and immune response dynamics
Federico Spataro

10.30 – 12.00 S25 Novel advances in cardiovascular prevention and cardiovascular disorders

Chairpersons: Alma Martelli, Danilo Norata

- 10.30 New approaches for the treatment of dyslipidemia **Alberto Corsini**
- 10.50 Targeting Lipoprotein(a): current and emerging therapeutic strategies for cardiovascular prevention
Francesca Zimetti
- 11.10 Immune dysregulation in cardiovascular disease - from novel mechanisms to therapeutic targeting
Pasquale Maffia
- 11.30 Recent advances in pulmonary hypertension **Claudia Raineri**

SPONSORED SESSION – Novo Nordisk

12.00 – 12.30 Obesity and the prevention of cardiovascular risk

Armando Genazzani, Pasquale Perrone Filardi, Paolo Sciattella

14.30 – 15.30 S35 Prevention of infectious diseases

Chairpersons: Giovanni Di Perri, Francesco Scaglione

- 14.30 Pre-Exposure Prophylaxis (PrEP) in HIV **Antonella Castagna**
- 14.50 RSV vaccination: a new frontier in infectious disease prevention TBD
- 15.10 Vaccination in oncological patients: a pharmacological perspective TBD

15.30 – 17.10 S7 Gene and cancer immunotherapy: unveiling molecular and cellular mechanism/s underlying immunotherapy

Chairpersons: Vincenzo Brancaleone, Stefania Marzocco

- 15.30 Reprogramming immune reactivity: the role of cell-specific metabolic genes in the tumor microenvironment **Francesca Fallarino**
- 15.50 Multi-omic profiling of the tumor ecosystem to unveil molecular and cellular mechanisms underlying immunotherapy **Rosalinda Sorrentino**
- 16.10 Insight into the relevance of cell-autonomous innate immunity in gene therapy **Carolina Petrillo**
- 16.30 Harnessing immune mechanisms to address unmet clinical needs in nasopharyngeal carcinoma
Romano Danesi
- 16.50 Innate lymphoid cells: a new frontier in cancer immunotherapy **Giuseppe Ercolano**

MEETING ROOM BERLINO

8.30 – 10.00 SY06 New therapeutic approaches in endothelial and cardiac dysfunction

Segreteria Scientifica

Provider e Segreteria Organizzativa



Chairpersons: Valerio Ciccone, Lorenzo Da Dalt

8.30 Preclinical evaluation of novel therapeutics in endothelial dysfunction: pharmacological profile of VEGF-mimetic peptides QK and HPLW-2 **Arianna Filippelli**

8.45 Efficacy and safety of pharmacological treatments in patients with transthyretin cardiac amyloidosis: a systematic review and meta-analysis **Eugenia Piragine**

9.00 Doxorubicin-induced inflammatory injury: simvastatin as a potential cardioprotective agent **Roberta Vitale**

9.15 eNOS hyper-persulfidation accounts for diabetes-associated vascular dysfunction. **Martina Smimmo**

9.30 Mechanistic insights into norbormide-induced cardiovascular toxicity in rats **Alessia Bichicchi**

9.45 Stress granules as mediators of cardiac damage by dysfunctional HDL during acute coronary syndrome **Chiara Oliviero**

10.00 – 12.00 S26 Next-generation oncology: degraders, ADCs and radioligand therapies

Chairpersons: Fabrizio Condorelli, Ambra Grolla, Cristina Travelli

10.00 Degraders: beyond the conventional inhibition-based strategies **Ambra Grolla**

10.20 Radioligand therapies: emerging frontiers in precision oncology **Mattia Riondato**

10.40 The revolution of ADCs **Armando Genazzani**

11.00 The use of network meta-analyses for indirect treatment comparisons: the example of multiple myeloma **Carlotta Galeone**

11.30 Advancing targeted oncology: the role of trastuzumab deruxtecan in next-generation antibody–drug conjugates **Romano Danesi**

14.30 – 16.00 S4 Cardiovascular applications of drugs used in the treatment of diabetes and obesity

Chairpersons: Alma Martelli, Francesco Rossi

14.30 Vascular effects of GLP-1 and other incretin mimetics **Elena Osto**

14.50 Exploiting the cardiovascular properties of "classical" antidiabetics: from "old" metformin to new metformin-based chemical entities **Vincenzo Calderone**

15.10 Evidence for the benefits of combining dapagliflozin with sacubitril/valsartan in cardiometabolic and age-related cardiac dysfunction **Antonella De Angelis**

15.30 cAMP/CREB/CSE axis accounts for the beneficial effect of dapagliflozin in cardiometabolic HFpEF **Valentina Vellecco**

16.00 – 17.30 S12 The evolution of obesity pharmacotherapy: innovations redefining targets, molecules, and interventions

Chairpersons: Silvana Gaetani, Valentina Vellecco

16.00 The evolution of obesity pharmacotherapy: potential benefits of therapies beyond incretins **Thomas Lutz**

16.20 Amylin and oleoylethanolamide at the interface of satiation and satiety: a multi-target strategy for obesity pharmacotherapy **Adele Romano**

16.40 Incretins at the interface of prandial lipid metabolism and inflammation: implications for metabolic pharmacotherapy **Andrea Baragetti**

Segreteria Scientifica

Provider e Segreteria Organizzativa



17.00 Beyond weight loss: dual GLP-1/glucagon agonists as disease-modifying therapy in MASLD
Matteo Monami

MEETING ROOM LONDRA

8.30 – 9.30 SY02 CGRP: migraine and beyond

Chairpersons: Cristina Benatti, Luigi Francesco Iannone

8.30 Study of effect of rimegepant in a murine model of endometriosis and migraine comorbidity
Chiara Sturaro

8.45 Beyond the Pain: how atogepant reshapes the overall migraine experience in Real-World
 Responders **Antonio Munafò**

9.00 Age- and sex-dependent differences in sumatriptan responsiveness in a CGRP-induced mouse
 model of migraine-like photophobia **Veronica Rivi**

9.15 Baseline Leeds Dependence Questionnaire scores are not associated with medication overuse
 persistence under anti-CGRP therapy in chronic migraine with medication-overuse headache **Andrea
 Burgalassi**

9.30 – 11.00 ROUND TABLE - TR1 Drug discovery and drug development: the role of technology transfer

Chairmen: Pier Luigi Canonico, Giulio Pompilio

Participants: Filippo Caraci, Monica Diluca, Beatrice Riva, Silvia Rossi, Laura Spinardi, Giuseppe Toffoli

11.00 –12.30 S21 New antibiotics and antimicrobial resistance

Chairpersons: Elisabetta Bigagli, Federico Pea

11.00 Tackling antimicrobial resistance with new BL/BLI in treating Gram-negative infections **Milo Gatti**

11.20 Tackling antimicrobial resistance with new long-acting antibiotics in treating Gram-positive
 infections **Dario Cattaneo**

11.40 Antimicrobial resistance in pediatric infections: epidemiological scenarios and implications for
 antimicrobial stewardship **Stefania Nobili**

12.00 New insights into pediatric infectious diseases: antibiotics, artificial intelligence and one-health
 approach **Silvia Garazzino**

14.30-16.00 S11 Eating disorders: new pharmacological strategies and therapeutic perspectives

Chairpersons: Paola Fadda, Maria Vittoria Micioni di Bonaventura

14.30 Unraveling neurodevelopmental dysregulation in anorexia nervosa: insights from multi-omics
Claudio D'Addario

14.50 Targeting epigenetic pathways in compulsive eating: entinostat produces lasting suppression of
 binge episodes in a rodent model **Giacomo Einaudi**

15.10 The neurobiology of anorexia nervosa: connectivity patterns, neurochemical gradients, and their
 clinical correlates **Enrico Collantoni**

15.30 Beyond the brain: peripheral epigenetic regulation of muscle dysfunction in binge eating disorders
 and therapeutic opportunities **Elena Conte**

Segreteria Scientifica

Provider e Segreteria Organizzativa



16.00-17.30 ROUND TABLE – TR2 The Integration of RWD and RWE into regulatory and early access processes in Italy

Chairpersons: Valentina Drago, Gianluca Trifirò

Participants: Mariangela Amoroso, Salvatore Crisafulli, Nello Martini, Francesca Patarnello, Sandra Petraglia, Patrizia Popoli

MEETING ROOM ISTANBUL

8.30-10.00 SY18 - Pulmonary disorders: emerging targets and technologies

Chairpersons: Ida Cerqua, Giuseppe Spaziano

8.30 Time course disease monitoring with computed tomography imaging: enhancing translational research from bench to bedside. **Elena Mantovani**

8.45 When smoke meets nanoplastics: a new driver of airway inflammation and COPD progression **Davida Mirra**

9.00 Targeting CD105: inhaled siRNA therapy for pulmonary fibrosis **Erika Esposito**

9.15 An innovative label-free approach for investigating epithelial-mesenchymal transition:

pharmacological characterization of TGF- β 1 effects in A549 cells

Francine Medjiofack Djeu

9.30 From environment to epithelium: biological and clinical effects of indoor and outdoor pollution in Campania's schoolchildren **Martina Simonelli**

9.45 Effect of elxacaftor/tezacaftor/ivacaftor therapy on serum lipoprotein functions in adults with cystic fibrosis **Marcella Palumbo**

10.00 – 12.00 S9 Precision medicine in respiratory diseases: novel biomarkers and therapeutic strategies

Chairpersons: Andrea Bianco, Antonietta Rossi

10.00 Biomarkers and artificial intelligence in precision medicine: new frontiers in asthma, COPD and ILD **Mario Salvatore Clerici**

10.20 Sex-specific epigenetic mechanisms in respiratory diseases: from biomarkers to therapeutic opportunities **Fiorentina Roviezzo**

10.40 Severe asthma and Type 2 inflammation: current biologics and emerging therapeutic targets **Giulia Costanzo**

11.00 Pulmonary fibrosis and Raynaud's Phenomenon: Early Diagnosis and Novel Antifibrotic Strategies **Barbara Ruaro**

11.30 New mechanisms of action in pulmonary fibrosis: from disease biology to therapeutic innovation **Martina Bonifazi**

14.30-16.00 S20 Early diagnosis and disease-modifying strategies in Alzheimer's disease: which evidence?

Chairpersons: Marco Bozzali, Filippo Caraci

14.30 Evolution of Alzheimer's disease biomarkers: from historical definitions to the discovery of novel therapeutic targets **Cristina Lanni**

14.50 Targeting amyloid in Alzheimer's disease: pharmacological profiles of monoclonal antibodies **Elena Marcello**

Segreteria Scientifica

Provider e Segreteria Organizzativa



15.10 The role of biomarkers for disease-modifying strategies in the diagnostic-therapeutic pathway for Alzheimer's disease **Alberto Benussi**

15.30 Passive immunotherapy in Alzheimer's disease: novel clinical evidence **Federica Agosta**

16.00 – 17.30 S15 The social brain: from neural circuits in mice to human therapeutic insights

Chairpersons: Gian Marco Leggio, Francesco Papaleo

16.00 Cortico-cortical transfer of socially derived information gates emotion recognition **Anna Maria Borrito**

16.20 Reciprocal cortico-amygdala connections regulate prosocial and selfish choices **Diego Scheggia**

16.40 Ketamine modulates emotion recognition by reversing age dependent Arc-driven deficits **Sebastiano Alfio Torrisi**

17.00 Bridging the scale from genes to systems-level readouts using transcriptomics **Giulio Pergola**

MEETING ROOM PARIGI

8.30 – 10.30 SY20 Convergent modulation of neuroinflammation and immunity through shared molecular pathways in CNS pathologies

Chairpersons: Majeda Muluhie, Irene Paterniti

8.30 Targeting the P2X7 receptor in α -synuclein-associated neuroinflammation and immunity: focus on Parkinson and Alzheimer diseases **Alessia Filippone**

8.45 What does the ACE2 overexpression reveals? Mapping the neuroimmune landscape in the humanized transgenic CAG-hACE2 mice **Carlotta Siddi**

9.00 BACE1 inhibition as a novel pharmacological strategy to counteract neuroinflammation in sepsis-associated encephalopathy **Gustavo Ferreira Alves**

9.15 Targeting the EZH2/H3K27me3 axis rescues CDK5/p53 signaling, mitochondrial dysfunction, and neuroinflammation in an in vitro model of Alzheimer's disease **Sarah Adriana Scuderi**

9.30 CIC-39 as a novel store-operated Ca^{2+} entry negative modulator: a non-immunosuppressive strategy for the treatment of multiple sclerosis **Luigi Azzarone**

9.45 Novel PUFA-Lipoic Acid Conjugates as dual-action neuroprotective agents: targeting oxidative stress and neuroinflammation in Alzheimer's disease cell models **Agnese Graziosi**

10.00 Pharmacological blockade of IL-1 β signaling with anakinra rescues behavioral and synaptic deficits in an α -synuclein model of Parkinson's disease **Federica Servillo**

10.15 Leukemia-driven neuroinflammation: linking systemic disease to CNS alterations in AML and CLL **Vjola Tusha**

10.30-11.30 Drug combinations as the modern paradigm: opportunities and challenges

Annalisa Capuano, Dario Lidonnici, Patrizia Popoli

11.30-12.30 Artificial Intelligence in Healthcare

Introduction: Antonio Addis

Participants: Robert Nisticò, Giulio Pompilio, Massimo Riccaboni

Segreteria Scientifica

Provider e Segreteria Organizzativa



12.30-13.30 Institutional review board network

Jacopo Angelini, Francesco Rossi

14.30 – 16.00 S2 Intestinal inflammation and tissue remodeling: from mechanisms to anti-fibrotic strategies

Chairpersons: Matteo Fornai, Barbara Romano

14.30 Diet-driven intestinal fibrosis: lipids and B-cells as key regulator of tissue remodeling **Stefania Vetrano**

14.50 Rethinking intestinal fibrosis: the role of the endocannabinoidome system in tissue remodeling **Maria Francesca Nani**

15.10 New anti-fibrotic agents based on biological products **Stefania Bruno**

15.30 PPAR agonists in cholestatic liver diseases **Laura Cristoferi**

16.00 – 17.30 S10 The senescence–inflammation axis: nutraceutical and pharmacological strategies for prevention and therapy

Chairpersons: Fabiana Morroni, Antonio Speciale

16.00 Neuroinflammation in Huntington's disease: therapeutic potential of senolytic drugs **Andrea Tarozi**

16.15 Targeting the senescence–inflammation axis in acute myeloid leukemia: nutraceutical and pharmacological potential of cucurbitacin D from *Elaeocarpus hainanensis* **Domenico Delfino**

16.30 Bioactive agents targeting the senescence-inflammation axis: focus on adipose tissue **Francesco Cimino**

16.45 The senescence–inflammation axis in Alzheimer's disease: microglia–oligodendrocyte interactions and therapeutic perspective **Morena Zusso**

17.00 The carnosine journey: unveiling its translational and therapeutic potential as anti-inflammatory and neuroprotective agent in Alzheimer's disease **Giuseppe Caruso**

17.30 – 18.30 Molecular Tumor Board Network

Marzia Del Re, Cristiano Chiamulera

27 November 2026

13.00 – 14.30 POSTER SESSION 4

AUDITORIUM

17.30 – 18.30 Pipeline session

Chairman: Armando Genazzani

18.30 – 20.00 SIF General Assembly

Monica Diluca, Armando Genazzani

Segreteria Scientifica

Provider e Segreteria Organizzativa



MEETING ROOM MADRID

8.30 – 9.30 SY23 At the crossroads of eating disorders and addictive behaviors: converging mechanisms towards translational treatment opportunities

Chairpersons: Carlo Cifani, Francesca Mottarlini

8.30 Eating disorders and addiction: converging neurocognitive and metabolic mechanisms **Laura Di Lodovico**

8.45 Deciphering the molecular signature of compulsive exercise as a translational phenotype in anorexia nervosa **Francesca Mottarlini**

9.00 Oxytocin receptor distribution in olfactory–limbic circuits relevant for reward and motivational salience in a mouse model of anorexia nervosa **Barbara Eramo**

9.15 Antagonism of the dopamine D4 receptor (D4R) blocks compulsive highly palatable food intake in a female rat model of binge eating **Luca Botticelli**

09.30 – 11.30 S3 Bispecific antibodies: from the laboratory to the clinic

Chairpersons: Giuseppe Nocentini, Giuseppe Toffoli

9.30 Bispecific (& multispecific) antibodies in cancer therapy: rational development and target selection **Mariangela Figini**

9.50 Key features defining the disposition of bispecific antibodies and their efficacy in vivo **Antonello Di Paolo**

Bispecific antibodies in hematologic tumors: current landscape and therapeutic advances

10.10 Lymphomas **Umberto Vitolo**

10.30 Myeloma **Michele Cavo**

10.50 Bispecific antibodies in solid tumors: novel evidence and future perspectives **Carmine Pinto**

11.10 Bispecific antibodies in cancer therapy: regulatory requirements and health technology assessment **Giuseppe Toffoli**

11.30 – 12.30 CAR-T: precision mechanisms and therapeutic innovation

Introduction: **Armando Genazzani**

11.30 CAR-T in onco-hematology: precision mechanisms and therapeutic innovation **Simona Sica**

12.00 CAR-T beyond oncology: opportunities and sustainability **Armando Genazzani**

14.30 – 16.00 S6 Dyshomeostasis of non-neuronal cells as a novel and early pharmacological target in neurodegenerative disorders

Chairpersons: Mariagrazia Grilli, Maria Angela Sortino

14.30 Microglial protection in early neurodegeneration: impact of external insults **Sara Merlo**

14.50 Glia-Neural Stem Cell Interactions in neurodegeneration and stress **Emanuela Pessolano**

15.10 Astrocyte-driven oligodendrocyte dysfunction in Alzheimer's disease: molecular pathways of damage and rescue **Caterina Scuderi**

15.30 Neuroglia in Amyotrophic lateral sclerosis: translating glial biology into therapeutic strategies **Fabiola De Marchi**

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 15.50 Skeletal muscle as a non-neuronal driver of ALS: from calcium dyshomeostasis to therapeutic intervention **Serenella Anzilotti**

MEETING ROOM DUBLINO

8.30 – 10.00 SY14 Natural compounds and barrier functions: new evidence between gastroprotection, metabolism, and aging

Chairpersons: Maria Francesca Nani, Lara Testai

- 8.30 New preclinical insights into the gastroprotective role of *Castanea sativa* Mill. and *Cistus x incanus* L. combination **Stefano Piazza**

- 8.45 Multifunctional biological activities of *Angelica sinensis* extract in human skin cell models **Veronica Cocetta**

- 9.00 *Citrus pomace*-derived phytocomplexes preserve intestinal barrier integrity and modulate gut microbial metabolism under inflammatory conditions **Mariarosaria Ingegneri**

- 9.15 Synergistic anticancer and gastroprotective effects of *Ulva pertusa* in 5-fluorouracil therapeutic regimen **Alessio Ardizzone**

- 9.30 Bioactivity of *Allium ursinum* leaf extracts: a phytochemical and functional study **Mariachiara Gabriele**

- 9.45 Protocatechuic acid counteracts hypoxia-induced adipocyte senescence and metabolic dysfunction in murine 3T3-L1 Adipocytes **Maria Sofia Molonia**

10.00 – 11.30 The next generation of clinical pharmacology and hospital pharmacy: contributions from specialty trainees

Chairpersons: Alma Martelli, Gianluca Trifirò

- 10.00 Development of innovative pharmacogenomic biomarkers for the personalization of therapy with thiopurines in early onset inflammatory bowel disease patients **Giulia Zudeh**

- 10.15 Biosimilar switching in rheumatologic and dermatologic patients: a semi-automatic multidisciplinary approach to ensure appropriateness and sustainability **Alessandra Angarano**

- 10.30 Post-marketing safety of GLP-1 Analogs: a disproportionality analysis of semaglutide and liraglutide in diabetes and weight management using eudravigilance **Victoria Nikitina**

- 10.45 Antibiotic prescribing practices and consumption in a secondary healthcare structure in Bissau: toward context-adapted AMS strategies **Giustina Stano Marilisa**

- 11.00 Pharmacogenetic-guided dosing approach for warfarin therapy: a pharmacoeconomic evaluation of randomized clinical trials **Salavatore Zarrella**

- 11.15 Neurophysiological signatures of alcohol and cocaine craving: preliminary results from the ReBECCA study **Elia Amalfi**

11.30 – 12.30 ROUND TABLE: TR6 Medicines in the environment: monitoring, treatments and intervention strategies

Chairpersons: Giovanna Paolone, Raffaella Sorrentino

Participants: Antonella Abollino, Nicola Frison, Vitalia Murgia, Stefano Polesello

14.30 – 16.00 S29 Teaching 2.0: innovative methodological approaches

Segreteria Scientifica

Provider e Segreteria Organizzativa



Chairpersons: Carla Ghelardini, Anna Maria Pittaluga

14.30 Innovating university courses through a blended learning model—integrating Massive Open Online Courses (MOOCs) and Open Educational Resources (OER) **Maria Renza Guelfi**

14.45 Team-Based Learning (TBL) and pharmacology: a possible combination? **Antonella Lotti**

15.00 Pharmacy Services: Educational and practical simulation of professional activities **Marco**

Milanese

15.15 Assembly of the SIF CNFU Section

Carla Ghelardini

16.00-16.30 Assembly of the SIF Education Section

Giuseppe Cirino

MEETING ROOM BERLINO

8.30 – 9.30 SY19 The metastatic partnership: vascular, stromal and immune interaction in the journey of circulating tumor cells

Chairpersons: Michela Campolo, Valerio Ciccone

8.30 The ascitic compartment in ovarian cancer: circulating tumor cells and tumor–microenvironment crosstalk **Francesca Gorini**

8.45 Hydrogen sulfide–driven reprogramming of the glioblastoma microenvironment: cancer-associated fibroblast (CAF) activation, sphingosine-1-phosphate (S1P) axis and stemness **Giovanna Casili**

9.00 Circulating tumour cell cluster dynamics in triple-negative breast cancer **Federica Carolina Balestrero**

9.15 Beyond angiogenesis: pro-inflammatory activated pericytes in breast cancer progression **Marianna Moro**

9.30 – 11.10 S23 Pharmacogenetics in personalized medicine

Chairpersons: Rossana Roncato, Alessio Squassina

9.30 Targeting metabolism in oncology Armando Genazzani

9.50 Pharmacogenetics in the Italian National Health System: a roadmap to clinical implementation **Erika Cecchin**

10.10 Pharmacogenetics and Therapeutic Drug Monitoring: integrating tools for personalized therapy **Jessica Cusato**

10.30 Integrating liquid biopsy into personalized therapeutic strategies **Marzia Del Re**

10.50 Implementing clinical pharmacogenomics in Europe: challenges and future perspectives **Jesse Swen**

11.10 – 12.30 S19 The role of pharmacology in clinical precision oncology

Chairpersons: Antonio D’Avolio, Enrico Mini

11.10 Bioinformatic (AI) models-based approaches in the development and clinical application of anticancer drugs **Stefano Fogli**

11.30 Therapeutic drug monitoring as a tool to enhance efficacy and reduce toxicity in cancer therapy **Lucia Lisi**

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 11.50 Clinical relevance of drug - drug interactions in cancer patients **Emanuel Raschi**
 12.10 New phenotypes of cardiotoxicity induced by cancer therapies **Giorgio Minotti**

14.30 – 16.00 S30 The challenges faced nationally in clinical pharmacology

- 14.30 The global pharmaceutical context
 14.45 Globalization of clinical trials: is Italy/Europe competitive?
 15.00 Post-marketing and pre-marketing evidence generation: is Italy competitive?
 15.15 The risks and benefits of defining “overlapping” therapeutic activity between different drugs
 15.30 Key areas of improvement in the Italian academia-industry partnerships
 15.45 Key areas of improvement in the Italian industry-academia partnerships

16.00 – 16.30 Assembly of the SIF Clinical Pharmacology Section

Annalisa Capuano

MEETING ROOM LONDRA

8.30 – 10.00 SY04 Drug targeting of cancer cells

Chairpersons: Stefania Nobili, Federica Papaccio

- 8.30 Hypoxia-Driven Metabolic Reprogramming Promotes Therapy Resistance in AML **Lorenzo Manfreda**

- 8.45 TRPV3 loss rewires intestinal epithelial homeostasis toward stemness and a pro-tumorigenic state
Maria Miraglia

- 9.00 Targeting the Wnt/ β -catenin pathway in adrenocortical carcinoma cell lines **Andrea Abate**

- 9.15 Proteomic signatures of acquired doxorubicin resistance in breast cancer: focus on 2D and 3D models and extracellular vesicles **Alessandra Cusimano**

- 9.30 In vivo chemical reactions to target and detect tumour hypoxia **Marta Serafini**

- 9.45 Role of miR-223 in NLRP3 inflammasome modulation in oral squamous cell carcinoma orthotopic model **Laura Cucinotta**

10.00 – 11.30 Emerging strategies in cardiovascular prevention

Chairpersons: Vincenzo Calderone

- 10.00 Decoupling haemostasis and thrombosis: FXIa inhibition, new frontier in secondary stroke prevention **Andrea Zini**

- 10.30 New therapeutic strategies in the management of hypertension **Cristina Giannattasio**

- 11.00 The quest to cover unmet needs in uncontrolled hypertensive patients **Massimo Volpe**

15.30 – 16.30 Assembly of the SIF Early Career Pharmacology Group

Maria Antonietta Riemma

MEETING ROOM ISTANBUL

8.30 – 10.00 SY22 Novel and 3R-compliant platforms for early translational research in rare diseases

Chairpersons: Elisabetta Bigagli, Ramona Meanti

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 8.30 Apoptosis and motor deficits in SPG76 hereditary spastic paraplegia: Calpain 2 inhibition as therapeutic strategy **Giulia Guarato**
- 8.45 Brain organoids to identify therapeutic targets for neurodevelopmental disorders induced by thyroid deficiency as for the rare Allan-Herndon-Dudley Syndrome (AHDS) **Francesca Ciarpella**
- 9.00 Development of a functional human neuronal model for the study of ataxia-telangiectasia **Giulia Lecchi**
- 9.15 Integrative modelling of degenerative and metabolic disorders in drosophila melanogaster: pathogenic mechanisms and experimental therapeutic approaches **Simona Del Quondam**
- 9.30 ATM-knockout human neural progenitors as a sophisticated cellular platform for investigating ataxia-telangiectasia pathophysiology and for drug repurposing strategy **Giulia Boni**
- 9.45 Towards a 3R-compliant integrated approach: innovative preclinical platforms for rare neuromuscular diseases and channelopathies **Lisamaura Tulumiero**

10.00 – 11.30 ROUND TABLE - TR7 Transitional care in rare diseases: regulatory and therapeutic pathways for orphan drugs and advanced therapies

Chairpersons: Annamaria De Luca, Armando Genazzani

Participants: Maria Adelaide Bottaro, Pier Luigi Canonico, Luisa De Sanctis, Graziana Diez Roux, Andrea Marcellusi, Patrizia Popoli, Dario Roccatello, Annalisa Scopinaro, Giovanna Scroccaro

11.30-12.00 Givinostat in Duchenne muscular dystrophy: an Italian story of scientific innovation, translational research and patient partnership **Paolo Bettica**

SPONSORED SESSION – LUNDBECK

12.00-12.30 Beyond individual syndromes: how should the regulatory approach to DEEs evolve **Emilo Russo**

14.30 – 15.30 ROUND TABLE - TR5 Safety and Regulatory Framework for Medicinal Plants and Nutraceutical

Chairpersons: Francesca Borrelli, Antonella Di Sotto, Annabella Vitalone

Participants: Alessandro Assisi, Marco Biagi, Gioacchino Calapai, Francesca Menniti Ippolito, Monia Lenzi

15.30-16.30 S34 Unlocking Transient Receptor Potential (TRP) channels: new frontiers in drug discovery

Chairpersons: Angelo Antonio Izzo, Francesco de Logu

15.30 How trp channels shape cancer progression: trpv3 as gatekeeper of invasiveness **Ester Pagano**

15.50 An unexpected and druggable trpa1 signaling in schwann cells driving chronic pain **Romina Nassini**

16.10 Not just brainy, but also brawny: a TR(i)P into latest discoveries **Fabio Arturo Iannotti**

MEETING ROOM PARIGI

8.30 – 10.00 SY17 - Deconstructing neurodevelopmental disorders: from neurobiological mechanisms to clinical trials

Chairpersons: Maria Italia, Michele Santoni

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 8.30 Altered post-trauma neural activity in the basolateral amygdala is associated with susceptibility to PTSD **Giulia Chiacchierini**
- 8.45 IAMA-6 successfully completed phase-1 trial, progressing clinical development in neurodevelopmental disorders **Annalisa Savardi**
- 9.00 Convergent Negr1 upregulation drives core behaviors and identifies an autism biomarker **Mariam Marie Chellali**
- 9.15 Cardiac interoception and insular cortex: a pathway to understanding social deficits in autism **Alessandra Panzeri**
- 9.30 Unraveling the differential impact of prenatal THC and CBD exposure on neurodevelopmental trajectories: long-term molecular and behavioral outcomes **Serena Di Martino**
- 9.45 Prenatal microglial depletion alters neurodevelopmental trajectories following Early Immune Activation in mice **Naomi Ciano Albanese**

11.00 – 12.30 S17 Marine Pharmacology: a sea of opportunities

Chairpersons: Mario Dell'Agli, Giustino Orlando, Lara Testai

- 11.00 Pharmacological research inside blue economy: from results to perspectives **Paola Nieri**
- 11.20 Evaluation of the anti-inflammatory and anti-hyperalgesic properties of *Posidonia oceanica* (L.) *Delile* in preclinical pain models **Laura Micheli**
- 11.40 Marine bioactive against cancer from *Zostera marina* **Paola De Cicco**
- 12.00 From marine natural products to cancer therapy: the case of lurbinectedin **Lorenzo D'Ambrosio**

13.00-14.30 Phase I Clinical Trial Network

Romano Danesi, Sandra Sigala, Maurizio Tagliatela

14.30 – 16.00 S32 Sex-aware pharmacological research: from scientific evidence to experimental practice

Chairpersons: Flavia Franconi, Luigia Trabace

- 14.30 From concept to practice: implementing sex-aware pharmacology in experimental research **Antonietta Rossi**
- 14.40 Rethinking sex in pharmacology: from bias to sex contextualism **Ilaria Campesi**
- 15.00 From data to evidence: statistical strategies to detect sex differences in pharmacological research **Giovanni Sotgiu**
- 15.20 Are the 3Rs and the need for gender balance in animal studies conflicting? **Giuliano Grignaschi**

28 November 2026

AUDITORIUM

11.30 – 12.30 Plenary Lecture: Lysosomal calcium signalling: from discovery to the clinic

Introduced by Armando Genazzani

Speaker: Antony Galione

12.30 – 13.00 Conclusions and awards

Segreteria Scientifica

Provider e Segreteria Organizzativa



Armando Genazzani

MEETING ROOM MADRID

8.30 – 10.00 SY13 Joint SIF–SIICA Symposium: targeting immunometabolism – Young investigators rewiring immune function for next-generation therapies

Chairpersons: Marco Gargaro, Eleonora Timperi

8.30 Non-enzymatic function of IDO1 as immunometabolic driver in the tumor microenvironment: therapeutic implications. **Sofia Rossini**

8.45 Targeting IDO1 to rewire cDC1 metabolism and restore anti-tumor immunity **Giada Mondanelli**

9.00 CD71-dependent iron metabolism in RORyt⁺ Tregs shapes intestinal homeostasis and tumor immunity **Alessandra Pinzon Grimaldos**

9.15 Effects of genetic lysosomal acid lipase deficiency on immune cell function: focus on dendritic cells. **Carola Garavaglia**

9.30 Caloric restriction as a metabolic-immunological strategy to improve clinical and cellular outcomes in relapsing-remitting multiple sclerosis **Alessandra Colamatteo**

9.45 A siRNA-based approach to target Oncostatin M in bone marrow macrophages as an anti-inflammatory and pro-regenerative therapy for diabetic vascular disease **Carlotta Boscaro**

10.00 – 11.30 ROUND TABLE - TR8 Clinical Pharmacology and the National Health System

Chairpersons: Erika Cecchin, Concita Rafaniello

Participants: Valeria Conti, Salvatore Crisafulli, Marzia Del Re, Antonello Di Paolo, Liberata Sportiello, Gabriele Stocco

MEETING ROOM DUBLINO

8.30 – 9.30 SY30 Frailty in complex comorbidities: from mechanisms to emerging therapeutic strategies

Chairpersons: Arianna Pani, Maria Antonietta Riemma

8.30 Frailty in accelerated aging: sex- and time-dependent responses to a multi-drug treatment in SAMP8 mice **Martina Monaco**

8.45 Delphi expert consensus to develop recommendations for medication adherence interventions in older adults with multimorbidity and polypharmacy **Stefano Scotti**

9.00 Pharmacological and clinical impact of medication review on older people in general practice: a systematic review and meta-analysis of experimental studies **Irene Cristini**

9.15 Polypharmacy in chronic heart failure: the impact of medication review and the role of the multidisciplinary team **Miriam Traficante**

9.30 – 10.30 SY03 Intestinal microbiota in extra-digestive disorders

Chairpersons: Clelia Di Salvo, Carla Petrella

9.30 Bridging gut dysbiosis and pain: modulatory effect of N-palmitoyl D-glucosamine **Federica Ricciardi**

9.45 Microbiota-mediated crosstalk between the gut and the vascular system: functional insights for cardiovascular protection of probiotic-derived formulations **Lorenzo Flori**

Segreteria Scientifica

Provider e Segreteria Organizzativa



- 10.00 Long lasting sex-dependent influence of antibiotic-induced dysbiosis and *Lactobacillus rhamnosus* GG (ATCC 53103) on gastrointestinal motility and behaviour **Annalisa Bosi**
- 10.15 OEA-producing *Lactobacillus paracasei* F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese mice **Irene Palenca**

MEETING ROOM BERLINO

08.30 – 10.00 ROUND TABLE - TR3 Medical publishing: challenges, integrity and innovation

Chairpersons: Emilio Clementi, Gianluca Trifirò

Participants: Carla Carnovale, Emilio Clementi, Luca De Fiore, Gianluca Trifirò, Francesco Visioli

10.00 – 11.30 SY28 Advances in alternative research methods: from drug discovery to personalized medicine

Chairpersons: Elisabetta Caiazza, Elena Lucarini

8.30 A novel UHPLC-MS/MS method for the plasmatic quantification of cabotegravir from MITRA - Volumetric Absorptive Microsampling (VAMS) devices **Sara Soloperto**

8.45 Modeling chemotherapy-induced peripheral neuropathy in human dorsal root ganglia organoids **Maria Giovanna Cataldi**

9.00 hiPSC-Derived DRG organoids model differential vulnerability to sorbitol-induced neurotoxicity and neuroprotection by MAP4K inhibitors in diabetic neuropathy **Daniel Venturi**

9.15 Modelling hypertension-associated neuroinflammation using a human millifluidic system **Benedetta Mercuriali**

9.30 Development of 3D models of leiomyosarcoma for the evaluation of doxorubicin–peposertib combination therapy **Antonella Simone**

9.45 Methylphenidate modulates alpha-synuclein/Synapsin III co-pathology in iPSC-derived striatal organoids from multiple system atrophy patients **Gaia Faustini**

MEETING ROOM LONDRA

8.30 – 10.00 SY05 Targeting cellular and structural components of the tumor microenvironment

Chairpersons: Raffaella Belvedere, Monica Notarbartolo di Villarosa

8.30 From tumor to microenvironment: impact of 5-azacytidine adjuvant drug targeting Annexin A1 on oral squamous cell carcinoma progression **Nunzia Novizio**

8.45 Decoding hypoxia-adapted regulatory T cells in cholangiocarcinoma through spatial proteomics **Luigi Cari**

9.00 Overcoming therapy resistance in a rare cancer: targeting the tumor microenvironment in adrenocortical carcinoma **Mariangela Tamburello**

9.15 Antitumor activity of *Moringa oleifera* extract in multiple myeloma cell and in bone marrow microenvironment model **Ilaria Saltarella**

Segreteria Scientifica

Provider e Segreteria Organizzativa



9.30 Targeting ERO1 α triggers tumor immunosurveillance in triple-negative breast cancer **Alessandro Cherubini**

9.45 Loss of AIM2 limits tumor growth in a mouse model of lung adenocarcinoma resistant to immunotherapy **Chiara Colarusso**

10.00 – 11.30 S8 Inflammation and response to pharmacological treatment in psychiatric disorders

Chairpersons: Annamaria Cattaneo, Edoardo Spina

10.00 Targeting Inflammation to improve symptoms in non-responder patients: the importance of immune stratification **Annamaria Cattaneo**

10.20 Machine learning for capturing inflammation-related heterogeneity in mood disorders **Benedetta Vai**

10.40 Impact of inflammation on antidepressant pharmacokinetics: navigating literature evidence, areas of uncertainty, and perspectives from plasma concentration data **Giuseppe Cicala**

11.00 Molecular bridges among lifestyles, depressive symptoms and cardiometabolic traits **Alessandro Gialluisi**

MEETING ROOM ISTANBUL

8.30 – 10.00 SY07 Substance use disorders in adolescence and adulthood: neurobiological adaptations, behavioral outcomes, and their clinical relevance

Chairpersons: Nicholas Pintori, Laura Rullo

8.30 A procedure to identify persistent and effort-independent individual differences in preference for heroin over rewarding social interaction **Ginevra D'Ottavio**

8.45 Stress-related neuroadaptations following adolescent exposure to the synthetic cannabinoid 5F-MDMB-PICA **Francesca Caria**

9.00 Cebranopadol: a novel dual NOP/MOP receptor agonist to treat fentanyl use disorder and fentanyl induced respiratory depression in a rat model of addiction. **Manthoula Olga Kyratzi**

9.15 Prolonged nicotine exposure, via electronic cigarettes, selectively enhances the transcription of Bdnf/TrkB and elevates dynorphin peptide and OLIG2 levels in the rat VTA **Camilla Morosini**

9.30 Prenatal THC exposure alters kynurenine pathway and stress responsivity in the ventral tegmental area **Edoardo Tiziani**

9.45 Investigating the ability of LSD to revert fentanyl-induced maladaptive neuroplastic changes **Fabio Ruto**

10.00 – 11.30 S13 Post-transcriptional regulation: the molecular interface between health and disease

Chairpersons: Nicoletta Galeotti, Alessia Pascale

10.00 Translational control as a therapeutic target **Alessandro Quattrone**

10.20 MicroRNAs and ocular diseases **Chiara Bianca Maria Platania**

10.40 Modulation via drug therapy of HuR in multiple sclerosis **Nicoletta Marchesi**

11.00 A possible role for the RNA-binding protein HuD in Amyotrophic Lateral Sclerosis **Alessandro Rosa**

11.15 Post-transcriptional mechanisms in cellular aging **Sofia Quadrino**

Segreteria Scientifica

Provider e Segreteria Organizzativa



MEETING ROOM PARIGI

8.30 – 9.30 SY09 - Real-world evidence of biologic drugs in immune mediated inflammatory diseases

Chairpersons: Irma Convertino, Andrea Spini

8.30 Real-world effectiveness, treatment persistence, and safety of biologic therapies in inflammatory bowel diseases: a prospective pharmacovigilance study **Maria Antonietta Barbieri**

8.45 Biologics in psoriasis and psoriatic arthritis: a one-year real-world study from Calabria **Lorenza Guarnieri**

9.00 Evaluating the representativeness of pivotal trials for biologics in pediatric immune-mediated inflammatory diseases: a population-based study using the Italian VALORE distributed database network. **Chiara Bellitto**

9.15 Output from the Veneto Region Working Group on high-cost drugs for immune-mediated inflammatory diseases: harmonizing prescribing appropriateness and cost-containment regional governance **Giacomo Vitturi**

9.30 – 10.30 SY16 Stress across the lifespan: mechanistic insights and novel therapeutic perspectives

Chairpersons: Natasha Irrera, Luísa Teixeira Santos

9.30 Targeting hypothalamic histaminergic neurons to modulate stress resilience: pharmacological and chemogenetic approaches **Alessia Costa**

9.45 Early-life stress: from later psychopathologies to pharmacological interventions **Giulia Federica Mancini**

10.00 Abnormal trajectory of dopaminergic neurodevelopment and stress-related behaviors following perinatal paracetamol exposure **Valeria Serra**

10.15 Early life stress and long term negative behavioural outcomes dissecting the role of the gut microbiome in clinical and preclinical studies **Floriana De Cillis**

10.30-11.30 In-training clinical pharmacologists/toxicologists and hospital pharmacists: the SIF Contest

Il presente documento è da considerarsi strettamente riservato. Il programma sarà reso definitivo e divulgabile una volta ricevute le conferme da parte dei relatori invitati

Segreteria Scientifica



Provider e Segreteria Organizzativa

